New York Life Investment Management LLC raised its holdings in shares of Solventum Corporation (NYSE:SOLV – Free Report) by 39.7% during the third quarter, HoldingsChannel reports. The fund owned 41,376 shares of the company’s stock after purchasing an additional 11,759 shares during the quarter. New York Life Investment Management LLC’s holdings in Solventum were worth $3,647,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. Clearstead Trust LLC boosted its holdings in shares of Solventum by 61.0% in the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after acquiring an additional 150 shares during the period. Laurel Wealth Advisors LLC purchased a new position in shares of Solventum in the third quarter valued at $29,000. JNBA Financial Advisors raised its stake in shares of Solventum by 71.9% during the 2nd quarter. JNBA Financial Advisors now owns 507 shares of the company’s stock valued at $39,000 after purchasing an additional 212 shares during the period. Ameritas Advisory Services LLC bought a new stake in shares of Solventum during the 2nd quarter valued at $47,000. Finally, Ancora Advisors LLC bought a new stake in shares of Solventum during the 2nd quarter valued at $56,000.
Solventum Stock Performance
NYSE SOLV opened at $88.85 on Monday. The company’s 50 day simple moving average is $87.53 and its two-hundred day simple moving average is $78.95. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.03 and a quick ratio of 0.72. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $94.16. The stock has a market capitalization of $15.08 billion, a PE ratio of 99.83, a P/E/G ratio of 1.27 and a beta of 0.69.
Analyst Ratings Changes
SOLV has been the topic of a number of recent research reports. Stifel Nicolaus increased their price objective on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. BTIG Research reaffirmed a “buy” rating on shares of Solventum in a report on Friday, November 6th. Mizuho set a $113.00 target price on Solventum in a report on Thursday, August 6th. Wells Fargo & Company upped their price target on Solventum from $89.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday, November 6th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Solventum has an average rating of “Moderate Buy” and an average price target of $90.27.
Read Our Latest Report on Solventum
About Solventum
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
Recommended Stories
- Five stocks we like better than Solventum
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
